Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667)

To be considered for this study, you must be a child or young adult between 3 and 25 years old and have a new diagnosis of classical Hodgkin Lymphoma. Doctors will look at the stage of your cancer to determine which group you might fit into within the study. It's important that your cancer can be measured by doctors.

There are also some general health requirements, meaning your body and organs need to be working well enough to take part. If you've had an organ transplant or specific stem cell treatments in the past five years, or if you've already had treatments using similar new drugs, you won't be able to join this particular study. Women who are pregnant or breastfeeding cannot participate.

Certain precautions regarding contraception are also in place for both male and female participants of childbearing potential to ensure safety during the study period.

If you decide to take part in this study, you will receive a new drug called pembrolizumab along with standard chemotherapy, which might include medicines like doxorubicin, vinblastine, or dacarbazine, among others. Some patients might also receive radiotherapy, which uses X-rays to treat cancer.

You will have regular visits to the hospital for treatment and check-ups. During these visits, doctors will monitor your health closely, perform tests, and assess how the treatment is working. The study will carefully follow your progress to see the effects of the treatment. The total duration of your participation in the study will depend on your specific treatment plan and how you respond to the medications, but it will involve ongoing assessments and follow-up.